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The aim of this study was to investigate histamine blood concentration in subjects suﬀering from diﬀerent types of ischemic
heart diseases during the period of eight days. Our results showed that the histamine blood level was associated with diﬀerent
types of ischemic heart diseases. The blood histamine level in all investigated patients was signiﬁcantly higher when compared to
control subjects (44.87 ± 1.09ngmL−1), indicating the increase of histamine release in patients suﬀering from coronary diseases.
In patients suﬀering from ACS-UA and ACS-STEMI, the second day peak of histamine level occurs (90.85 ± 6.34ngmL−1 and
121.7 ± 6.34ngmL−1, resp.) probably as the reperfusion event. Furthermore, our data suggest that histamine can be additional
parameter of myocardial ischemia along with cardiac speciﬁc enzymes and may prove to be an excellent single prognostic marker
for multitude of ischemic heart diseases.
1.Introduction
Histamine, a low-molecular-weight amine synthesized from
L-histidine in the reaction catalyzed by L-histidine decar-
boxylase, is known to activate the four G protein-coupled
receptors: H1, H2, H3 and H4, through which it is involved
in the regulation of several physiological processes [1].
Although it is contained in almost all tissues in human
organism, it is most frequently found in mast cells and
basophilic leukocytes. This biogenic amine is released by
endothelial cells, aggregating platelets, lymphocytes, and
monocytes/macrophages[2,3].Mastcellsandhistaminealso
have cranium-caudal distribution in the heart which means
that the largest quantity of this amine is in the right atrium
andtheleastinleftventricletissue.Increasednumberofmast
cells was found in coronary blood vessels adventitia in the
patients suﬀering from ischemic heart diseases, especially in
the narrow parts of blood vessels, or at the site of plaque rup-
ture[4,5].Obviousconnectionwasalsodeterminedbetween
coronarybloodvesselinﬂammationandmastcellsactivation
in the process of atherogenesis [6, 7]. Furthermore, previous
studies have shown that histamine aﬀects atherosclerosis
through H1 receptor mechanisms [8]. For example, his-
tamine enhances the expression of adhesion molecules in
vascular endothelial cells, thereby augmenting leukocyte-
endothelial cell interactions, an important onset event in
atherogenesis [8]. Moreover, this biogenic amine suppresses
hepatic LDL receptor expression and reduces plasma HDL
cholesterol in rats [9]. This suggests that histamine may play
an important role in lipoprotein metabolism, which may
be related to its role in the development of atherosclerosis.
Histamine has also been shown to increase smooth muscle
cell proliferation and migration and implicated in intimal
thickening and atherogenesis [6].
Histamine’s eﬀects on coronary arteries are the result of
multipleactionsofthismoleculeonbothsmoothmuscleand
endothelial cells. Relaxation and constriction of coronary
vessels have been widely reported as its eﬀects. These eﬀects2 Journal of Biomedicine and Biotechnology
are species speciﬁc and depend on dose of histamine,
diameter and initial vessel tone, and relative location within
thecoronarycirculation[10].Whenatheroscleroticcoronary
artery is concerned histamine is a vasoconstrictor [11].
On the other hand histamine is a proven endothelium-
dependent vasodilator which bound with H1 receptor of
endothelial cells activates endothelial nitric oxide synthase
[12–14].AlthoughthiseNOSupregulationmaybeprotective
under normal circumstances, as it increases NO production,
it may become harmful under conditions of oxidative stress
when eNOS produces reactive oxygen species (ROS) at the
expense of NO [15–18]. Also, it is shown that histamine
produces coronary dilation via H2 receptor, which is not
endothelium dependent [11, 12], as well as through H2- and
H3-dependent mechanism involving the generation of nitric
oxide [19].
As said above, histamine is also released from the
aggregating platelets, and these observations suggested a
possible role of this amine in the pathogenesis of acute
coronary syndrome (ACS) [20]. Furthermore, histamine via
H1 receptors induces expression of tissue factor (TF), a key
enzyme in the activation of coagulation [5]. The elevated
levels of quantity and activity of TF antigen have been
detected in plasma and atherectomy specimens of patients
with unstable angina and acute myocardial infarction [5, 6].
Recent research clearly indicates a great role of histamine
ininﬂammationprocessesthroughitsinﬂuenceoncyclooxy-
genases and increased production of PGI2 and PGE2 [6].
Considering the fact that inﬂammation is the key factor for
atherosclerosis, ﬁnally, it is essential to point out the fact that
blood histamine alone may be a good prognostic indicator
for ischemic event (ACS), better than CRP, even when it is
combined with lipid indexes [21].
Up to now research showed that the patients suﬀering
from ischemic heart diseases (stable coronary artery dis-
ease (SCAD) and acute coronary syndrome (ACS)) have
statistically signiﬁcantly higher total blood histamine than
the population without these diseases [21]. However, these
data about histamine blood levels in ACS patients have
been obtained only within the ﬁrst 24 hours of acute
event, which is why the aim of this study was to examine
histamine blood concentration in subjects suﬀering from
ischemic heart diseases during the period of eight days.
Furthermore, we intended to analyze whether histamine
blood concentrations in patients depend on diﬀerent types
of ischemic heart diseases such as stable coronary artery
disease, acute coronary syndrome, nonocclusive type, or
acute coronary syndrome, occlusive type.
2.MaterialsandMethods
All researches were performed according to the ethical stan-
dards of the local Ethics Committee and Helsinki Declara-
tion.
2.1. Subjects. Four groups of subjects were observed. Group
I: control group included age, sex, and risk factors matched
volunteers without coronary disease. All volunteers under-
went an initial clinical assessment that included a clinical
history taking, a physical examination, electrocardiography,
standard blood measurements, and stress echocardiography.
Furthermore, none of the volunteers had shown any allergy
manifestations (n = 32). Group II: subjects suﬀering from
stable coronary artery disease (SCAD patients) determined
by symptoms during physical activity, stress echocardiog-
raphy, coronarography, and so forth (n = 28). SCAD is
an abbreviation for stable angina. Patients suﬀering from
this disease manifest symptoms (like chest pain, fatigue,
e t c . )a n dc h a n g e si nE C G( s u c ha sn e g a t i v eT - w a v eo rS T
depression) under exertion while the values of troponin I
and CKMB remain normal. Group III: subjects with acute
coronary syndrome, nonocclusive type (unstable angina or
ACS-UA patients) determined by symptoms during resting
period, acute electrocardiographic changes, and coronarog-
raphy (n = 26). Apart from chest pain these subjects
also have changes in ECG (such as negative T-wave or the
positivity of previously negative T-wave), while the values of
troponin I and CKMB are within physiological range. Group
IV: subjects with acute coronary syndrome, occlusive type
(ACS-STEMI patients) determined by typical accelerating
symptoms, acute electrocardiographic changes and levels of
serum enzymes (troponin I, CKMB), and coronarography
(n = 37). ACS-STEMI is abbreviation for transmural
myocardial infarction. Patients suﬀering from this form of
acutecoronarysyndromeinadditiontoprolongedchestpain
also have changes in ECG (such as elevation of ST segment),
and the values of troponin I and CKMB are increased.
Patients in groups II, III, and IV were hospitalized
in the Medical Centre (Kragujevac, Serbia). First blood
samples were collected within either (1) the ﬁrst 24 h of
their acute events (ACS-UA and ACS-STEMI patients) after
initial medical stabilization or (2) the ﬁrst 24h of their
hospitalization in Medical Center of Kragujevac (SCAD
patients). The remaining blood samples were collected daily
for the following 7 days. The measurement of whole blood
histamine was performed as described below. Data points
included sex, age, illness, work activities, pain, history of
exercise, smoking habits, and other observations (such as
anger or nervousness, etc.), as well.
2.2. Biochemical Procedures. The estimation of whole blood
histamine was performed immediately after the collection
from the study subjects using modiﬁed Shore’s method
for the ﬂuorometric assay of histamine in the tissue [22].
This method is precise, sensitive, and speciﬁc for histamine
and involves extraction of histamine into n-butanol (Polskie
Odczynniki Chemiczne S.A., Poland) from alkalinized per-
chloric acid (Mallinckrodt Baker B.V., Holland) blood sam-
ple, return of the histamine to an aqueous solution and con-
densationwitho-phthalaldehyde(OPT)(SIGMA,Germany)
to yield a product with strong and stable ﬂuorescence, which
is measured in a spectroﬂuorometer (Perkin-Elmer LS-5B).
2.3. Statistical Analysis. All results are presented as means
± S.E.M. (standard error of the mean) and analyzed afterJournal of Biomedicine and Biotechnology 3
Table 1: Clinical characteristics of investigated groups.
Control SCAD ACS-UA ACS-STEMI
Age (years)∗ 54±20 56±18 56±20 58±18
Male sex (%) 56 58 60 60
Hypertension (%) 20 78 77 74
Diabetes mellitus (%) 10 42 23 21
Smoking (%) 62 63 65 59
Heredity (%) 31 47 55 58
Lipids in blood (%) 30 84 77 82
∗Age values in all investigated groups are represented as mean ± S.E.M.
determination of normality of distribution with Student’s t-
test and ANOVA test, where P value of <.05 was considered
statistically signiﬁcant.
3. Results
This study examined, as described in Section 2, patients
with stable coronary artery disease (SCAD), acute coronary
syndrome, nonocclusive type (ACS-UA), and acute coronary
syndrome, occlusive type (ACS-STEMI), as well as control
group. Clinical characteristics of analyzed groups are shown
in Table 1.
The analyzed groups were uniform in terms of age, sex,
smoking habits, or physical activity. Hypertension, heredity,
and diabetes mellitus type II, as well as total cholesterol,
low-densitylipoproteins(LDLs),andtriglyceridesweremore
frequent in patients with ischemic heart disease than in those
of control group (see Table 1).
Intermsofmedicationusagethegroupsdiﬀeredascould
be expected. Beta-blockers use was the highest in SCAD
patients (80%) and the least in the control group (10%)
while it ranged from 60% in ACS-UA patients to 25% in
ACS-STEMI patients. The usage of calcium channel blockers
was the highest in SCAD and ACS-UA patients (40%),
intermediate in ACS-STEMI patients (25%), and the least
in control group (5%). ACE inhibitor usage was similar in
all patients (about 50%), but much lower in control group
(10%). The usage of nitrates was almost equal in all patients
(about80%)versusnoneincontrol.Antiplateletsdrugs,such
as clopidogrel, were taken by ACS patients (UA and STEMI).
Fibrinolytics were used only by ACS-STEMI patients. All the
patients in heart disease groups were taking acetylsalicylic
acid in comparison to 40% of the control group. It is
importanttounderlinethefactthattherewerenostatistically
signiﬁcant diﬀerences in histamine blood concentrations
among patients in the same group with diﬀerent therapy
(P>. 05).
Histamine blood concentrations in the control group, as
well as in patients with coronary diseases (SCAD, ACS-UA
and ACS-STEMI), during the eight-day period are presented
in Figure 1. Histamine blood concentrations in patients with
diﬀerent types of coronary diseases (SCAD, ACS-UA and
ACS-STEMI) remained increased in comparison with the
control group during the whole testing period. Whole blood
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Figure 1: Histamine blood concentration (ngmL−1)i nc o n t r o l
group (n = 32), as well as in the patients with coronary diseases:
stable coronary artery disease (SCAD, n = 28), acute coronary
syndrome, nonocclusive type (ACS-UA, n = 26), and acute
coronary syndrome, occlusive type (ACS-STEMI, n = 37), during
the testing period of eight days. The data are presented by means ±
SEM.
histamine concentration in the control group was 44.87 ±
1.09ngmL−1.
The highest increase of histamine was in ACS-STEMI
patients, who had 2- to 3-fold more of this biogenic
amine in blood than those in control group (Figure 1).
Furthermore, histamine blood concentration in ACS-STEMI
patients achieved one peak value on the second day of
their acute events (127 ± 6.34ngmL−1), after which point
histamine blood level steadily decreased throughout the
testingperiodremainingsigniﬁcantlyhigherwhencompared
with the corresponding histamine blood levels in the other
analyzed groups.
Intermediate increase of histamine blood concentration
was recorded in ACS-UA patients, where values remained
signiﬁcantly lower than histamine blood concentrations
in ACS-STEMI patients during the entire testing period.
The highest increase of histamine blood concentrations
in ACS-UA patients occurred on the second day (90.85
± 6.34ngmL−1), the same as in ACS-STEMI patients
(Figure 1). During the ﬁrst ﬁve days of histamine blood
analysis concentrations in ACS-UA patients were signiﬁ-
cantly higher than in SCAD patients, whereas there were
no signiﬁcant diﬀerences in this respect between these two
groups in the last three days.
WhenSCADpatientsareconcerned,thehistamineblood
concentration was signiﬁcantly increased in comparison
with the control group on one hand and signiﬁcantly
lower than that in ACS-STEMI patients on the other hand
throughout the testing. During the eight-day observation,
concentrations of histamine in patients with stable angina
did not vary considerably on daily basis. The lowest value of4 Journal of Biomedicine and Biotechnology
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Figure 2: Troponin I blood concentration (ngmL−1)i nc o n t r o l
group (n = 32), stable coronary artery disease patients (SCAD,
n = 28), acute coronary syndrome, nonocclusive type, patients
(ACS-UA, n = 26), and acute coronary syndrome, occlusive type,
patients (ACS-STEMI, n = 37) during the eight-day period of
testing. Troponin I blood concentrations in control, SCAD, and
ACS-UA groups were in normal physiological range during the
whole investigated period (less than 0.01ngmL−1). The data are
presented by means ± SEM.
74.8 ± 4.1ngmL −1 was measured on the last day, while the
highest, measured on the third day, was 79.7 ±3.1ngmL −1.
Troponin I blood concentration (ngmL−1)i nS T E M I ,
ACS-UA, and ACS-STEMI patients and subjects of control
group during the eight-day period is shown in Figure 2.
Troponin I blood values were within normal physiological
range (less than 0.01ngmL−1) during the whole testing
period in control, SCAD, and ACS-UA groups. On the
other hand, troponin I blood concentrations in ACS-STEMI
patients were signiﬁcantly increased. Troponin I blood level
in ACS-STEMI patients achieved peak value in the ﬁrst
24 hours, which is much higher (3.2 ± 0.23ngmL−1)
than physiological ranges for this cardiac speciﬁc enzyme
(<0.01ngmL−1) after which point it steadily decreased till
the end of the period remaining signiﬁcantly higher.
CKMB blood concentrations (UL−1) in control group
and SCAD, ACS-UA, and ACS-STEMI patients during the
eight-day period are shown in Figure 3.C K M Bb l o o dv a l u e s
remained within normal physiological range (between 0 and
25 UL−1)i nc o n t r o lg r o u pa sw e l la si nS C A Da n dA C S - U A
patients. On the other hand, CKMB blood concentrations
in ACS-STEMI patients were signiﬁcantly increased on the
ﬁ r s ta n ds e c o n dd a y( s e eFigure 3). CKMB level in ACS-
STEMI patients achieved a peak value in the ﬁrst 24 hours
of their acute events (4 times higher than physiological value
for this cardiac speciﬁc enzyme), and after that point its level
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Figure 3: CKMB blood concentration (UL−1) in control group
(n = 32), stable coronary artery disease patients (SCAD, n =
28), acute coronary syndrome, nonocclusive type, patients (ACS-
UA, n = 26), and acute coronary syndrome, occlusive type,
patients (ACS-STEMI, n = 37) during the eight-day period
of testing. CKMB blood concentrations in control, SCAD, and
ACS-UA groups were in normal physiological range during the
whole investigated period (between 0 and 25UL−1). The data are
presented by means ± SEM.
decreased and returned to its normal physiological range
after the third day of analysis.
4. Discussion
For more than two decades histamine has been considered
to be one of the vasoactive metabolites which are released in
coronary circulation during myocardial ischemia. Clinically,
increased blood histamine levels have been described in
patients with ischemic heart diseases by Kounis and Zavras
[23]. Furthermore, experimental studies have documented
that coronary histamine mostly originates from cardiac mast
cells [24] and activated platelets [25, 26].
Up to now the histamine blood levels in the patients
suﬀering from ischemic heart diseases have been measured
only in the ﬁrst 24 hours of acute event [21]. However,
there is a deﬁciency of data regarding histamine blood
concentration in patients suﬀering from ischemic heart
diseases for longer periods, which is why this study examines
histamine blood concentration during the eight-day period
in subjects suﬀering from diﬀerent types of ischemic heart
diseases.
In this study (Table 1), observed groups were uniform
in terms of age, sex, smoking habits, and physical activity.
Hypertension, heredity, and diabetes mellitus type II, as well
as lipids in the blood were more frequent in patients with
ischemic heart disease than in the control group. These dataJournal of Biomedicine and Biotechnology 5
are in accordance with previous reports [27–31], reﬂecting
relationship between mentioned risk factors and coronary
endothelial dysfunction.
Statistically speaking, signiﬁcantly higher levels of blood
histamine are found in SCAD, ACS-UA, and ACS-STEMI
patients compared with control group during the whole
period (Figure 1).
SCAD patients showed signiﬁcantly increased histamine
blood concentration (up to 79.5 ± 3.6ngmL−1)c o m p a r e d
with the control group (44.87 ± 1.09ngmL−1). Obtained
values were lower than those in ACS-STEMI patients during
the whole eight-day period, in comparison to ACS-UA
patients where they were lower only during the ﬁrst ﬁve days.
The process of atherosclerosis leads to lipids accumula-
tion in the blood vessel wall, activating cardiac mast cells,
which, in turn, cause an increase in coronary histamine con-
centration [6].Furthermore,atherosclerosisleadstonarrow-
ing of epicardial coronary arteries, thus compromising the
ﬂow of coronary vascular bed, resulting in inadequate blood
supply to the heart muscle (ischemia). Myocardial ischemia
and consequent hypoxia also promote the degranulation of
cardiacmastcells,leadingtothereleaseofhistamine[24,32].
This can be the cause of signiﬁcantly higher and sustained
histamine blood concentration in SCAD patients compared
with the control group. Our results demonstrate that the
increased concentration of histamine in patients with stable
formofcoronaryarterydiseasewasnotsigniﬁcantlydiﬀerent
depending on the time of blood sampling during the eight-
day monitoring and remained at about 80ngmL−1.
Figure 1 shows that ACS-UA patients had higher his-
tamine blood concentration compared with the control
group during the entire monitoring, and for the ﬁrst ﬁve
days these values were signiﬁcantly higher than those in
SCAD patients as well. On the sixth day the measured value
was 81.1 ± 1.2ngmL −1, while on the seventh and eighth
days the measured concentrations of histamine in ACS-UA
patients were below 80ngmL−1. These results suggest that
ACS-UA patients have signiﬁcantly higher blood histamine
levels on the 1st admission day (84.8 ± 1.2ngmL −1)a s
well as within the next four days when compared to SCAD
patients. Interestingly, the peak of histamine increase in
the ACS-UA patients (90.85 ± 2.4ngmL −1) occurs on the
second day indicating additional histamine release within
the ﬁrst 48 hours. In the last three days, none of the
measured concentrations diﬀered signiﬁcantly from the
blood histamine concentration of SCAD patients for the
same period. This indicates stabilization and transition of
unstable form of disease to a stable one.
Pathophysiological basis for unstable angina pectoris is
unstable atherosclerosis plaque complicated with endothe-
lial damage, activation of platelets and spasm (reversible
ischemia) [33]. The role of histamine in the erosion or
rupture of coronary plaque is not deﬁned, but there are
investigations that show that chronic activation of mast
cells in the atherosclerotic lesions predisposes the subject
to this event [6]. Further, the proportion of activated and
degranulated adventitial mast cells was found to be the
highest in the segments with ruptured plaques [32] leading
to higher histamine release [6]. The damaged endothelium
leadstoactivationandsecretionofplateletwhich,inaddition
to ADP, coagulation factors, growth factors, and serotonin
[34], secretes histamine too [20]. Furthermore, via H1
receptors histamine induces expression of tissue factor (TF),
akeyenzymeintheactivationofcoagulation[5].Theprocess
of coagulation with the formation of a thrombus results in
the narrowing of blood vessels, ischemia, and hypoxia which
leads to further activation of mast cells and platelets, which
then release new amounts of histamine [26, 35, 36]. All
this indicates the reasons of signiﬁcantly increased histamine
concentration in our patients with unstable angina. Also,
unstable angina is characterized by dynamic narrowing due
to spasm of the coronary arteries in addition to the mechan-
ical narrowing. Spasm, together with the process of coagula-
tion,signiﬁcantlyincreasesischemialeadingtothehistamine
release from activated mast cells [26]. Further, Sakata et al.
[37] observed that the coronary histamine is elevated shortly
before coronary spasm, as discussed elsewhere [38], and
Kounis and Zavras [23] suggest that chest pain in patients
with unstable angina triggered by coronary spasm can be
p r o v o k e db yh i s t a m i n e .T h u sav i c i o u sc i r c l ei sc r e a t e d :( 1 )
erosion or rupture of unstable atherosclerotic plaque leads to
mechanical constriction that causes the release of histamine,
(2) released histamine increases coronary artery spasm, and
(3) spasm exacerbates ischemia and hypoxia releasing new
amounts of histamine. Perhaps the reason for several days
of increased concentrations of histamine in our ACS-UA
patients is the given mechanism. However, unstable angina
is characterized by reversible ischemia, which was conﬁrmed
in our study by the negative values of cardiac enzymes. So
the stabilization of plaque leads to better blood circulation
and consequently less hypoxia, which could be the reason
for signiﬁcantly lower concentrations of histamine in our
patients on the sixth, seventh, and eighth days of testing.
ThebloodlevelsoftroponinI(Figure 2)aswellasCKMB
(Figure 3) were in normal physiological range in ACS-UA
patients during the testing. This suggests that in our study
histamine appears to be a more sensitive parameter for
myocardial ischemia than the cardiac speciﬁc enzymes.
Of all the four groups, the highest increase of histamine
blood concentration was measured in ACS-STEMI patients
(Figure 1). Our results show that histamine blood concen-
tration in ACS-STEMI patients achieved a peak value (121.7
± 6.34ngmL−1) on the second day of their acute events,
after which point histamine blood level decreased to the
end of the observed period steadily remaining signiﬁcantly
higher when compared with the corresponding histamine
bloodlevelsintheothergroups.Thesedataareinaccordance
with previous data that histamine blood concentration
increases as the disease becomes more severe [6]. ACS-
STEMI is the most serious form of unstable coronary
disease characterized by irreversible ischemia and necrosis
of myocardial tissue, caused by occlusion of blood vessel
[33]. Cardiac troponins are the biomarkers of choice for
detection of myocardial necrosis, and the determination of
these enzymes is very useful for the measurement of the
extent of necrosis [39–42]. Also, it is noted that histamine
blood level has been dependent on the infarct size [32].
The increased number of adventitial mast cells was found6 Journal of Biomedicine and Biotechnology
to correlate with the progression of atherosclerosis, and their
presence is particularly high in areas of arterial thrombosis
[6]. Importantly, the highest numbers of intimal mast cells
have been found at sites of rupture and/or erosion in infarct-
relatedcoronaryarteries[7].Wemustnotforgetthatinthese
patients thrombin and collagen stimulate platelets to release
histamine as well [25, 43].
These data are in accordance with our results that
ACS-STEMI patients have the highest histamine blood
concentration compared with the other groups and its level
remained above 80ngmL−1 during the whole eight-day
period (Figure 1). Acute coronary event with occlusion of
coronary blood vessel causes severe injury to neighboring
cells (mast cell necrosis) and leads to massive histamine
release as illustrated by high histamine values in our patients.
Furthermore, troponin I blood concentration as well as
CKMB concentration in ACS-STEMI patients was signiﬁ-
cantly increased, and their values peaked in the ﬁrst 24 hours
(Figures 2 and 3). These data are in accordance with other
reports [44], proving the correlation between myocardial
cell injury and release of cardiac speciﬁc enzymes. Also,
as in ACS-UA patients, in ACS-STEMI patients, additional
histamine release has been detected within 48 hours after
admission. This peak of histamine concentration on the
second day was even more pronounced when compared
with ACS-UA patients. The additional histamine release on
the second day in ACS-UA and ACS-STEMI patients was
not detected in SCAD patients which can be explained as
the consequence of the reperfusion after previous ischemia.
The fact that histamine is released in ischemia-reperfusion
conditions is well known [45, 46].
Previous studies have shown that half-life of plasma
histamine and plasma troponin I measures in minutes and
days, respectively [47, 48]. Because of troponin long half-
life, it is not useful for detection of early reinfarction, which
is why the rise of histamine blood concentration may be a
parameter for detection of such events.
Finally, it is well known that smoking habit is also a
risk factor for atherosclerosis, and nicotine present in smoke
extract has been shown to activate human mast cells [6, 49]
and histamine release. However, in our study, the groups
did not diﬀer in smoking habits (Table 1). It is important
to underline the fact that there were no statistically signif-
icant diﬀerences in histamine blood concentration between
patients in the same group according to smoking habits
(P>. 05). That means that mast cell activation provoked by
smoking did not signiﬁcantly inﬂuence histamine release in
our study. Furthermore, in our study there were no statisti-
callysigniﬁcantdiﬀerencesinhistaminebloodconcentration
among subjects in control group according to the incidence
of hypertension, type II diabetes, or dyslipidemias, and there
are no known data published indicating that such diseases
may have impact on histamine blood concentration.
5. Conclusions
In this study we investigated histamine blood concentration
in subjects suﬀering from diﬀerent types of ischemic heart
diseases (stable coronary artery disease, acute coronary
syndrome, nonocclusive type, and acute coronary syndrome,
occlusive type) during the eight-day testing period.
We found evidence that the histamine blood level is
associated with diﬀerent types of ischemic heart disease.
The histamine level in blood in all research subjects
was signiﬁcantly higher when compared to control subjects,
indicating the increase of histamine release in the patients
suﬀering from coronary diseases. In the patients suﬀering
from ACS-UA and ACS-STEMI, the second day peak of
histamine level occurs probably as the reperfusion event.
Furthermore, our data suggest that histamine can be
additional parameter of myocardial ischemia along with
cardiac speciﬁc enzymes such as troponin I and CKMB and
may prove to be an excellent single prognostic marker for
multitude of ischemic heart diseases.
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